DK1108034T3 - Svækkede salmonella SPI2-mutanter som antigenbærere - Google Patents
Svækkede salmonella SPI2-mutanter som antigenbærereInfo
- Publication number
- DK1108034T3 DK1108034T3 DK99946122T DK99946122T DK1108034T3 DK 1108034 T3 DK1108034 T3 DK 1108034T3 DK 99946122 T DK99946122 T DK 99946122T DK 99946122 T DK99946122 T DK 99946122T DK 1108034 T3 DK1108034 T3 DK 1108034T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell
- nucleic acid
- antigen
- acid molecule
- attenuated salmonella
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 108700008969 Salmonella SPI-2 Proteins 0.000 title 1
- 239000000969 carrier Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 101000823106 Equus caballus Alpha-1-antiproteinase 2 Proteins 0.000 abstract 2
- 210000005256 gram-negative cell Anatomy 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98116827 | 1998-09-04 | ||
| PCT/EP1999/006514 WO2000014240A2 (en) | 1998-09-04 | 1999-09-03 | Attenuated salmonella sp12 mutants as antigen carriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1108034T3 true DK1108034T3 (da) | 2008-11-10 |
Family
ID=8232583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99946122T DK1108034T3 (da) | 1998-09-04 | 1999-09-03 | Svækkede salmonella SPI2-mutanter som antigenbærere |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6936425B1 (es) |
| EP (2) | EP1970449B1 (es) |
| JP (1) | JP2002524077A (es) |
| AT (2) | ATE486940T1 (es) |
| AU (1) | AU5860599A (es) |
| BR (1) | BR9914479A (es) |
| CA (1) | CA2341349C (es) |
| CY (1) | CY1109387T1 (es) |
| DE (2) | DE69939264D1 (es) |
| DK (1) | DK1108034T3 (es) |
| ES (2) | ES2356863T3 (es) |
| PT (1) | PT1108034E (es) |
| WO (1) | WO2000014240A2 (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996017951A2 (en) * | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
| DK1108034T3 (da) * | 1998-09-04 | 2008-11-10 | Emergent Product Dev Uk Ltd | Svækkede salmonella SPI2-mutanter som antigenbærere |
| GB9910812D0 (en) * | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
| AU2003204710B2 (en) * | 1999-05-10 | 2006-08-03 | Microscience Limited | Attenuated microorganisms for the treatment of infection |
| EP1640013A3 (en) * | 2000-03-17 | 2007-02-21 | Pharmacia & Upjohn Company LLC | Inactivated Salmonella vaccines |
| ATE300949T1 (de) * | 2000-03-17 | 2005-08-15 | Pharmacia & Upjohn Co Llc | Ssa inaktivierte salmonella impfstoffe |
| GB0105924D0 (en) * | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| DE60216099D1 (de) * | 2001-05-17 | 2006-12-28 | Creatogen Ag | Methode zum auffinden von abgeschwächten oder virulent-defekten mikroben |
| US8029777B2 (en) | 2004-08-13 | 2011-10-04 | Marshall Barry J | Helicobacter system and uses thereof |
| JP2008509168A (ja) | 2004-08-13 | 2008-03-27 | マーシャル，バリー，ジェー． | 細菌デリバリシステム |
| CN1276076C (zh) * | 2004-12-14 | 2006-09-20 | 华东理工大学 | 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用 |
| US20070134814A1 (en) * | 2005-12-09 | 2007-06-14 | Kajander E O | Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease |
| US8604178B2 (en) | 2006-09-18 | 2013-12-10 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses |
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| EP2152883A4 (en) * | 2007-05-10 | 2010-10-27 | Univ Arizona | RECOMBINANT BACTERIA COMPRISING VECTORS FOR THE EXPRESSION OF NUCLEIC ACID SEQUENCES ENCODING ANTIGENS |
| EP2150616A4 (en) | 2007-05-10 | 2011-07-27 | Univ Arizona | REGULATED ANTIGEN SYNTHESIS AND / OR REGULATED ATTENUATION FOR IMPROVING VACCINATE IMMUNOGENICITY AND / OR SAFETY |
| WO2008153772A2 (en) * | 2007-05-25 | 2008-12-18 | Emergent Product Development Gaithersburg Inc. | Chlamydia vaccine comprising htra polypeptides |
| WO2009046451A1 (en) * | 2007-10-05 | 2009-04-09 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting a protective immune response against c. perfringens |
| CN102037135A (zh) * | 2007-10-30 | 2011-04-27 | 阿肯色大学评议会 | 增强对有鞭毛的细菌的免疫反应的组合物和方法 |
| DK2214701T3 (en) | 2007-11-01 | 2016-12-12 | Univ Arkansas | CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria |
| US8703153B2 (en) * | 2008-06-16 | 2014-04-22 | Prokarium Ltd. | Salmonella vectored vaccines against Chlamydia and methods of use |
| WO2010017383A1 (en) | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| WO2010045620A1 (en) | 2008-10-17 | 2010-04-22 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae |
| WO2010048322A1 (en) * | 2008-10-21 | 2010-04-29 | Emergent Product Development United Kingdom | Use of e. coli surface antigen 3 sequences for the export of heterologous antigens |
| JP4575498B2 (ja) * | 2009-02-20 | 2010-11-04 | 株式会社東芝 | 磁気記録媒体の製造方法 |
| US9163219B2 (en) * | 2009-04-14 | 2015-10-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Single expression vector for generation of a virus with a segmented genome |
| WO2010141143A2 (en) * | 2009-04-21 | 2010-12-09 | Vivocure, Inc. | Engineered avirulent bacteria strains and use in medical treatments |
| US8518658B1 (en) * | 2009-04-27 | 2013-08-27 | University Of South Florida | ATP-bioluminescence immunoassay |
| WO2010135563A1 (en) | 2009-05-22 | 2010-11-25 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium and methods of antigen and nucleic acid delivery |
| US9045742B2 (en) * | 2009-05-29 | 2015-06-02 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant Edwardsiella bacterium |
| US9062297B2 (en) | 2010-01-13 | 2015-06-23 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Yersinia pestis vaccine |
| DK2525817T3 (en) | 2010-01-21 | 2017-10-02 | Univ Arkansas | Vaccine vectors and methods for enhancing immune responses |
| US8889121B2 (en) | 2010-01-22 | 2014-11-18 | The Arizona Board Of Regents For An On Behalf Of Arizona State University | Bacterium comprising a regulated rfaH nucleic acid |
| WO2011150421A2 (en) | 2010-05-28 | 2011-12-01 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium to decrease tumor growth |
| JP5746333B2 (ja) | 2010-06-09 | 2015-07-08 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | カンピロバクター感染を減少させるワクチン及び方法 |
| US8481052B2 (en) | 2011-05-17 | 2013-07-09 | Cj Cheiljedang Corporation | Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same |
| RU2510839C2 (ru) * | 2012-05-03 | 2014-04-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" | Вакцина ассоциированная против сальмонеллеза, эшерихиоза и вирусной геморрагической болезни кроликов |
| RU2496518C1 (ru) * | 2012-05-03 | 2013-10-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" | Способ изготовления вакцины ассоциированной против сальмонеллеза, эшерихиоза и вирусной геморрагической болезни кроликов |
| US9303264B2 (en) | 2012-05-18 | 2016-04-05 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Photosynthetic microorganisms expressing thermostable lipase |
| EP2852405B1 (en) * | 2012-05-23 | 2019-03-13 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof |
| ES2752190T3 (es) | 2012-09-14 | 2020-04-03 | Us Health | Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso |
| PT2956165T (pt) | 2013-02-14 | 2019-11-29 | Texas A & M Univ Sys | Composições e métodos de potenciação das respostas imunitárias frente a eimeria ou limitação de uma infeção por eimeria |
| WO2014144965A1 (en) * | 2013-03-15 | 2014-09-18 | Husseiny Elsayed Mohamed I | Attenuated salmonella bacteria and methods of using |
| US10376571B2 (en) | 2013-03-15 | 2019-08-13 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
| US9580718B2 (en) | 2013-06-17 | 2017-02-28 | Arizona Board Of Regents On Behalf Of Arizona State University | Attenuated live bacteria with increased acid resistance and methods of use thereof |
| US10987432B2 (en) * | 2013-09-05 | 2021-04-27 | The University Of Hong Kong | Therapeutic delivery and expression system, methods and uses thereof |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| EP3452069A4 (en) | 2016-05-03 | 2020-02-12 | The Board of Trustees of the University of Arkansas | Yeast vaccine vector with immunostimulating and antigenic polypeptides and method for using them |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| EP4045672A4 (en) * | 2019-10-18 | 2023-11-22 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR GENERATING ENHANCED IMMUNE RESPONSES AND RAPID ANTIBODIES PRODUCTION |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| WO2022271976A1 (en) * | 2021-06-24 | 2022-12-29 | Elanco Us Inc. | Attenuated salmonella, vaccines, and delivery platform |
| CN114292339B (zh) * | 2022-01-05 | 2022-08-09 | 武汉科前生物股份有限公司 | 鞭毛素突变体与非洲猪瘟抗原的融合蛋白及其应用 |
| CN114703214A (zh) * | 2022-03-03 | 2022-07-05 | 南京吉芮康生物科技研究院有限公司 | 一种抗丢失时空可控表达的新型质粒及其应用 |
| WO2024061748A1 (en) * | 2022-09-21 | 2024-03-28 | Prokarium Limited | Salmonella strain with chromosomally integrated landing pad |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US232165A (en) * | 1880-09-14 | Mechanical musical instrument | ||
| US1449502A (en) * | 1921-04-23 | 1923-03-27 | James G Diffendaffer | Restraining device |
| US1476164A (en) * | 1922-02-21 | 1923-12-04 | Michael J Manahan | Door and window shade and curtain clamp |
| US1903387A (en) * | 1930-08-20 | 1933-04-04 | Eaton Mfg Co | Automobile heater |
| US2103863A (en) * | 1936-12-28 | 1937-12-28 | Woodall Industries Inc | Visor construction |
| US2728467A (en) * | 1954-01-28 | 1955-12-27 | Glicker Herman | Parking tower structure |
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IN151589B (es) | 1978-12-22 | 1983-05-28 | Biogen Nv | |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US5210035A (en) | 1980-05-19 | 1993-05-11 | Board Of Trustees Of Leland Stanford Jr. University | Non-reventing live vaccines |
| US4837151A (en) | 1980-05-19 | 1989-06-06 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford University | Live vaccines comprising two mutations and foreign antigen |
| US4550081A (en) | 1980-05-19 | 1985-10-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Non-reverting salmonella |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US5397697A (en) | 1989-01-10 | 1995-03-14 | Ciba-Geigy Corporation | Identification of plant-responsive genes of bacteria |
| FR2664614B1 (fr) | 1990-07-11 | 1992-10-16 | Pasteur Institut | Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires. |
| SE9101433D0 (sv) | 1991-05-13 | 1991-05-13 | Marianne Hansson | Recombinant dna sequence and its use |
| EP0669989A1 (en) | 1991-08-22 | 1995-09-06 | Washington University | Polynucleotide probes for salmonella |
| AU2778992A (en) | 1991-10-07 | 1993-05-03 | Idaho Research Foundation Inc., The | Genetic construct for selection of homologous recombinants on a single selective medium |
| US5356797A (en) | 1991-11-15 | 1994-10-18 | Board Of Regents, The University Of Texas | Membrane expression of heterologous genes |
| WO1993010246A1 (en) | 1991-11-15 | 1993-05-27 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
| EP0668779A4 (en) | 1992-11-06 | 1996-08-21 | Univ Minnesota | Vaccine to protect against pasteurellosis - infection by P.multocida. |
| WO1994026933A1 (en) | 1993-05-13 | 1994-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Genetic footprinting: insertional mutagenesis and genetic selection |
| WO1996011708A1 (en) | 1994-10-18 | 1996-04-25 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
| WO1996017951A2 (en) | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
| US5700683A (en) | 1995-02-17 | 1997-12-23 | Pathogenesis Corporation | Virulence-attenuating genetic deletions deleted from mycobacterium BCG |
| EP0857214A1 (en) | 1995-10-16 | 1998-08-12 | Smithkline Beecham Plc | Novel saliva binding protein |
| AU7738396A (en) | 1995-11-14 | 1997-06-05 | General Hospital Corporation, The | Salmonella secreted proteins and uses thereof |
| AU4070097A (en) | 1996-08-16 | 1998-03-06 | Uab Research Foundation, The | Mucosal immunogens for novel vaccines |
| GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
| AU722326B2 (en) | 1997-02-14 | 2000-07-27 | Merck & Co., Inc. | Polynucleotide vaccine formulations |
| US6455323B1 (en) | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
| GB9804809D0 (en) | 1998-03-06 | 1998-04-29 | Wallis Timothy S | Attenuated salmonella:materials and methods relating thereto |
| US6585975B1 (en) | 1998-04-30 | 2003-07-01 | Acambis, Inc. | Use of Salmonella vectors for vaccination against helicobacter infection |
| DK1108034T3 (da) | 1998-09-04 | 2008-11-10 | Emergent Product Dev Uk Ltd | Svækkede salmonella SPI2-mutanter som antigenbærere |
| NZ527279A (en) | 1998-11-09 | 2005-05-27 | Microscience Ltd | Virulence genes and proteins, and their use |
| GB9910812D0 (en) | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
| WO2001032697A2 (en) | 1999-11-05 | 2001-05-10 | L'unite De Recherche En Biologie Moleculaire (Urbm) Des Facultes Universitaires Notre Dame De La Paix (Fundp) | Virulence genes and proteins from brucella melitensis, and their use |
| WO2001048208A2 (en) | 1999-12-23 | 2001-07-05 | Vmax Limited | Streptococcus pyogenes virulence genes and proteins and their use |
| GB0011108D0 (en) | 2000-05-08 | 2000-06-28 | Microscience Ltd | Virulence gene and protein and their use |
| GB0127657D0 (en) | 2001-11-19 | 2002-01-09 | Microscience Ltd | Virulence genes and proteins and their use |
| US7449178B2 (en) | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
-
1999
- 1999-09-03 DK DK99946122T patent/DK1108034T3/da active
- 1999-09-03 DE DE69939264T patent/DE69939264D1/de not_active Expired - Lifetime
- 1999-09-03 WO PCT/EP1999/006514 patent/WO2000014240A2/en active IP Right Grant
- 1999-09-03 AT AT08075560T patent/ATE486940T1/de not_active IP Right Cessation
- 1999-09-03 EP EP08075560A patent/EP1970449B1/en not_active Expired - Lifetime
- 1999-09-03 US US09/763,620 patent/US6936425B1/en not_active Expired - Fee Related
- 1999-09-03 ES ES08075560T patent/ES2356863T3/es not_active Expired - Lifetime
- 1999-09-03 AT AT99946122T patent/ATE403728T1/de active
- 1999-09-03 ES ES99946122T patent/ES2313792T3/es not_active Expired - Lifetime
- 1999-09-03 JP JP2000568983A patent/JP2002524077A/ja active Pending
- 1999-09-03 AU AU58605/99A patent/AU5860599A/en not_active Abandoned
- 1999-09-03 CA CA2341349A patent/CA2341349C/en not_active Expired - Fee Related
- 1999-09-03 BR BR9914479-4A patent/BR9914479A/pt not_active Application Discontinuation
- 1999-09-03 DE DE69942925T patent/DE69942925D1/de not_active Expired - Lifetime
- 1999-09-03 PT PT99946122T patent/PT1108034E/pt unknown
- 1999-09-03 EP EP99946122A patent/EP1108034B1/en not_active Expired - Lifetime
-
2004
- 2004-01-23 US US10/763,883 patent/US7700104B2/en not_active Expired - Lifetime
-
2007
- 2007-08-17 US US11/840,928 patent/US7955600B2/en not_active Expired - Fee Related
-
2008
- 2008-11-06 CY CY20081101270T patent/CY1109387T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE486940T1 (de) | 2010-11-15 |
| EP1970449A1 (en) | 2008-09-17 |
| ATE403728T1 (de) | 2008-08-15 |
| JP2002524077A (ja) | 2002-08-06 |
| WO2000014240A2 (en) | 2000-03-16 |
| ES2356863T3 (es) | 2011-04-13 |
| EP1108034A2 (en) | 2001-06-20 |
| WO2000014240A3 (en) | 2000-08-03 |
| CY1109387T1 (el) | 2014-07-02 |
| US7700104B2 (en) | 2010-04-20 |
| ES2313792T3 (es) | 2009-03-01 |
| US6936425B1 (en) | 2005-08-30 |
| EP1108034B1 (en) | 2008-08-06 |
| US7955600B2 (en) | 2011-06-07 |
| AU5860599A (en) | 2000-03-27 |
| PT1108034E (pt) | 2008-11-14 |
| CA2341349A1 (en) | 2000-03-16 |
| US20080075739A1 (en) | 2008-03-27 |
| BR9914479A (pt) | 2001-06-26 |
| DE69942925D1 (de) | 2010-12-16 |
| CA2341349C (en) | 2013-12-10 |
| US20040203039A1 (en) | 2004-10-14 |
| DE69939264D1 (de) | 2008-09-18 |
| EP1970449B1 (en) | 2010-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1108034T3 (da) | Svækkede salmonella SPI2-mutanter som antigenbærere | |
| Amano et al. | Deficiency of peptidoglycan and lipopolysaccharide components in Rickettsia tsutsugamushi | |
| BR9712971A (pt) | Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica | |
| NZ316787A (en) | Methods and compositions for the selective modification of nucleic acids | |
| CY1107656T1 (el) | Εξασθενημενοι μικροοργανισμοι για την αντιμετωπιση μολυνσης | |
| KR937000640A (ko) | 생 백신 | |
| ATE143690T1 (de) | Cd40 kodierende dna | |
| FI883722A0 (fi) | Alfa-amiderande enzymkompositioner och foerfaranden foer deras framstaellning och anvaendning. | |
| ATE219948T1 (de) | Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten | |
| FI960977A0 (fi) | Bakteeriperäiset eksportoidut proteiinit ja niihin perustuvat asellulaariset rokotteet | |
| Vanloubbeeck et al. | The immunology of Leishmania infection and the implications for vaccine development | |
| ATE401406T1 (de) | Hühner-anaemie-virus mutante, impfstoffe, und verwendungen basiert auf virusprotein vp3, oder dafür kodierende virus-sequenzen | |
| NO924576D0 (no) | Kloning og ekspresjon av gener som koder for arabinan-nedbrytende enzymer av sopp-opprinnelse | |
| DK0892054T3 (da) | Clostridium perfringens-vaccine | |
| IE810618L (en) | Pasteurella vaccines | |
| ATE107516T1 (de) | Pasteurella-impfstoff. | |
| DK0499681T3 (da) | pCTD-plasmid isoleret fra Chlamydia trachomatis serotype D, dets gener og proteiner, som kodes af dem; rekombinante plasmid | |
| CA3205817A1 (en) | Irradiated whole-cell immunogens of acinetobacter baumannii | |
| ATE435915T1 (de) | Spezifische nukleinsäuren und polypeptide aus krankheitserregenden stämmen von neisseria | |
| NZ295877A (en) | A vaccine comprising the helicobacter bacterium and its use | |
| Walker et al. | Opportunities and strategies to further reduce animal use for Leptospira vaccine potency testing | |
| HU9900534D0 (en) | Aviadenovirus | |
| CA2303722A1 (en) | Campylobacter vaccine | |
| O'HARA et al. | Mechanism of tetracycline resistance in Pseudomonas aeruginosa carrying an R factor | |
| DK230890A (da) | Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m. |